Identification and characterization of an HIV-2 antibody-positive blood donor in the United States

Transfusion

Volumn 38, Issue 2, 1998, Pages 189-193

  Sullivan, M T ^a,b   Guido, E A ^c   Metler, R P ^d   Schable, C A ^e   Williams, A E ^a   Stramer, S L ^c  

^a HOLLAND LABORATORY   (United States)

^b National Blood Data Resource Center   (United States)

^c AMERICAN RED CROSS BLOOD SERVICES   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; CASE REPORT; CROSS REACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMMUNOASSAY; IMMUNOBLOTTING; MALE; RISK FACTOR; SCREENING; SEQUENCE HOMOLOGY; SEXUAL BEHAVIOR; TRAVEL; VIRUS CHARACTERIZATION; VIRUS DETECTION; VIRUS ISOLATION;

EID: 0031919268     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.1998.38298193104.x     Document Type: Article

References (17)

1. Clavel F, Guétard D, Brun-Vézinet F, et al. Isolation of a new human retrovirus from West African patients with AIDS. Science 1986;233:343-6.
2. O'Brien TR, George JR, Epstein JS, et al. Testing for antibodies to human immunodeficiency virus type 2 in the United States. MMWR Morb Mortal Wkly Rep 1992;41(No. RR-12):1-9.
3. O'Brien TR, George JR, Holmberg SD. Human immunodeficiency virus type 2 infection in the United States. Epidemiology, diagnosis, and public health implications. JAMA 1992;267:2775-9.
4. Fang C, Layug L, Sandler SG, et al. Analysis of HIV-1 and HIV-2 Western blot band patterns (abstract). Transfusion 1993;33(Suppl):36S.
5. Gnann JW Jr, McCormick JB, Mitchell S, et al. Synthetic peptide immunoassay distinguishes HIV type 1 and HIV type 2 infections. Science 1987;237:1346-9.
6. AIDS due to HIV-2 infection - New Jersey. MMWR Morb Mortal Wkly Rep 1988;37:33-5.
7. Facts about human immunodeficiency virus type 2. Atlanta: Centers for Disease Control and Prevention, February 1997.
8. Update: HIV-2 infection among blood and plasma donors - United States, June 1992-June 1995. MMWR Morb Mortal Wkly Rep 1995;44:603-6.
9. Pau CP, Lee-Thomas S, Auwanit W, et al. Highly specific V3 peptide enzyme immunoassay for serotyping HIV-1 specimens from Thailand. AIDS 1993;7:337-40.
10. O'Brien TR, Polon C, Schable CA, et al. HIV-2 infection in an American. AIDS 1991;5:85-8.
11. Busch MB. To thy (reactive) donors be true (editorial)! Transfusion 1997;37:117-20.
12. Irwin KL, Olivo N, Schable CA, et al. Absence of human immunodeficiency virus type 2 infection among patients in a hospital serving a New York community at high risk for infection. Transfusion 1996;36:731-3.
13. Kawamura M, Yamazaki S, Ishikawa K, et al. HIV-2 in West Africa in 1966 (letter). Lancet 1989;1:385.
14. Ancelle R, Bletry O, Baglin AC, et al. Long incubation period for HIV-2 infection (letter). Lancet 1987;2:688-9.
15. Dufoort G, Courouce AM, Ancelle-Park R, Bletry O. No clinical signs 14 years after HIV-2 transmission via blood transfusion (letter). Lancet 1988;2:510.
16. Marlink R, Kanki P, Thior I, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994;265:1587-90.
17. Poulsen AG, Aaby P, Larsen O, et al. 9-year HIV-2-associated mortality in an urban community in Bissau, west Africa. Lancet 1997;349:911-4.